Core Viewpoint - The medical device sector experienced a rise of 1.42% on February 3, with Huakang Clean leading the gains, while the overall market indices also showed positive performance [1]. Group 1: Market Performance - The Shanghai Composite Index closed at 4067.74, up by 1.29% [1]. - The Shenzhen Component Index closed at 14127.1, up by 2.19% [1]. Group 2: Top Gainers in Medical Device Sector - Huakang Clean (301235) closed at 53.83, with a gain of 9.86% and a trading volume of 114,200 shares, amounting to a transaction value of 610 million yuan [1]. - Baocait (300246) closed at 13.15, up by 7.96% with a trading volume of 178,500 shares, totaling 229 million yuan [1]. - Yirui Technology (688301) closed at 119.24, increasing by 7.10% with a trading volume of 41,000 shares, resulting in a transaction value of 477 million yuan [1]. - Hualan Co. (301093) closed at 86.08, up by 6.45% with a trading volume of 60,900 shares, totaling 482 million yuan [1]. - Tianzhihang (688277) closed at 24.18, increasing by 6.10% with a trading volume of 159,300 shares, amounting to 379 million yuan [1]. Group 3: Market Outflows and Inflows - The medical device sector saw a net outflow of 253 million yuan from institutional investors and a net outflow of 112 million yuan from speculative funds, while retail investors had a net inflow of 365 million yuan [2]. - The detailed fund flow for individual stocks indicates varying levels of net inflow and outflow among different companies [3].

摘要 ： 随着临床应用的不断深入，MALDI-TOF MS的价值正从"快速鉴定"向"信息延展"演进。基于此，仪器 信息网对近年来的MALDI-TOF产品进行了梳理，以供读者参考。 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的 推送。 基质辅助激光解吸电离飞行时间质谱（MALDI-TOF MS）作为临床实验室的常规配置之一，以极 快的速度和高通量特性已广泛应用于血培养、尿液、呼吸道及其他临床样本的微生物鉴定流程中， 成为感染性疾病诊疗链条中的关键技术节点。 当 前 ， 耐 药 病 原 微 生 物 感 染 已 成 为 全 球 公 共 卫 生 领 域 的 重 大 挑 战 ， 每 年 导 致 数 百 万 人 死 亡 。 近 年 来，MALDI-TOF MS与机器学习（ML）技术的结合，为抗菌素耐药性（AMR）的快速检测提供 了新的解决路径。通过对质谱指纹信息的深度挖掘与建模分析，相关研究已将耐药性判读时间缩短 至1天甚至更短，为临床快速决策和抗菌药物精准使用创造了条件。 随着临床应用的不断深入，进口与国产质谱厂商相继推出新一代MALDI-TOF仪器： ...

近日，蓝帆医疗发布公告称，蓝帆医疗股份有限公司（以下简称"公司"）及子公司根据税务部门要求， 对健康防护事业部相关主体2020年度至2022年度跨境关联交易转让定价相关涉税事项开展特别纳税调整 自查。 经自查，公司及子公司需就相关税务事项补缴税款 16,956.09 万元，并对应加收利息。公司将依法按时 履行补缴义务。 (编辑：杨燕 林辰)关键字： 医疗 截至本公告披露日，本次事项不涉及税务行政处罚。 （蓝帆医疗公告） ...

证券日报网讯2月3日，天益医疗（301097）在互动平台回答投资者提问时表示，截至2026年1月30日， 公司股东总数为5165户。公司于2024年10月与费森尤斯子公司ProCureMedicalGmbH签订的《分销合 同》正正常履行中，2026年为合同正式生效首年，公司将按约定安排陆续交付产品。 ...

归创通桥(02190)盘中涨近7%，截至发稿，涨5.65%，报25.04港元，成交额1788.45万港元。 报告期内，公司通桥麒麟血流导向装置、神经血管导丝、UltraFree药物洗脱PTA球囊扩张导管、 ZYLOX Swan静脉腔内射频闭合导管等产品销售收入均实现较快增长。国际业务方面，公司海外市场销 售收入同比增长超过100%，在德国、法国、意大利等重点国家市场的渗透率持续提升。同期，公司国 际化战略实现关键突破，海外市场拓展全面提速。 消息面上，归创通桥近日发布盈喜。预期2025年全年净利润超过人民币2.4亿元，较去年同期大幅增长 约139.4%；营业收入超过人民币10.5亿元，同比增长约34.6%。归创通桥表示，2025年公司业绩表现亮 眼，主要受益于核心产品销售的强劲增长、海外业务的加速发展以及运营效率的持续优化。 ...

Core Viewpoint - Guichuang Tongqiao (02190) has announced a positive earnings forecast, expecting a significant increase in net profit and revenue for 2025, driven by strong sales of core products and international market expansion [1] Financial Performance - The company anticipates a net profit exceeding RMB 240 million for 2025, representing a substantial year-on-year growth of approximately 139.4% [1] - Projected operating revenue is expected to exceed RMB 1.05 billion, reflecting a year-on-year increase of about 34.6% [1] Product Performance - Sales revenue from key products such as the Tongqiao Qilin blood flow guiding device, neurovascular guidewire, UltraFree drug-eluting PTA balloon catheter, and ZYLOX Swan venous RF closure catheter have all experienced rapid growth [1] International Expansion - The company's international sales revenue has more than doubled year-on-year, with significant market penetration in key countries such as Germany, France, and Italy [1] - The internationalization strategy has achieved critical breakthroughs, accelerating the expansion into overseas markets [1]

智通财经APP讯，新华医疗(600587.SH)公告，公司全资子公司新华医疗康复产业(西安)有限公司于近日 收到陕西省药品监督管理局颁发的《医疗器械注册证》，相关产品名称为：四肢联动康复训练仪。 ...

Core Viewpoint - The establishment of the "Hong Kong Drug and Medical Device Supervision and Management Center" in 2026 marks a significant milestone for the regulation of drug and medical device innovation in Hong Kong, aiming to enhance the region's status as an international authority in this field [1][2] Group 1: Regulatory Developments - The Hong Kong government will implement a new "first-tier approval" mechanism for drug registration in 2026, allowing for independent evaluation and approval of drug and medical device safety and efficacy based on clinical data [1] - The first phase of the "first-tier approval" will cover registration applications for products with registered chemical elements, including new indications, dosages, and formulations, to gradually establish a comprehensive approval system [1] Group 2: Industry Support and Initiatives - The Hong Kong Department of Health will submit legislative proposals for regulating medical devices this year, encouraging the industry to prepare for the transition to a future statutory framework [1] - A "one-on-one" consultation service for applicants under the "1+" mechanism for new drug registration has been initiated, aiming to optimize the approval process without any fees during the current phase [2] - The Hong Kong Department of Health is closely monitoring the technological developments in innovative medical devices and will issue guidelines to assist the industry in meeting relevant requirements [1][2]

Investment Rating - The report does not explicitly state an investment rating for the company. Core Insights - Haisheng Medical is recognized as a national-level specialized and innovative "little giant" in the field of anesthesia and monitoring medical devices, with a comprehensive product offering and strong market presence in China [3][18]. - The company has a solid growth trajectory, with revenue expected to reach 304 million yuan in 2024, a slight decrease of 0.70% year-on-year, but showing positive growth in the first three quarters of 2025 with a revenue increase of 19.89% [3][12]. - The company has a robust technology matrix with 63 patents, including 13 invention patents, and has undertaken numerous significant technology projects at various governmental levels [3][18]. Company Overview - Haisheng Medical specializes in anesthesia and monitoring medical devices, serving major clinical departments such as anesthesia, ICU, and emergency [3][15]. - The company has established a strong brand and marketing network, with products used in over 600 top-tier hospitals, including prestigious institutions like Peking Union Medical College Hospital [5][12]. - The revenue composition for 2024 indicates that anesthesia products account for 52.60%, monitoring products for 36.59%, and surgical and nursing products for 10.47% [30][33]. Financial Performance - In 2024, the company is projected to achieve a gross margin of 52.09% and a net margin of 23.35% [12][30]. - The net profit attributable to the parent company for 2024 is expected to be approximately 70.92 million yuan, reflecting a year-on-year decline of 9.12% [12][30]. - The company’s R&D expenses for 2024 are estimated at 16.16 million yuan, representing 5.32% of revenue, with a year-on-year growth of 21.67% in the first three quarters of 2025 [5][12]. Industry Analysis - The medical device market in China is rapidly growing, with the market size expected to increase from 440.3 billion yuan in 2017 to 1.1544 trillion yuan by 2024, reflecting a compound annual growth rate (CAGR) of 14.76% [4][18]. - The low-value medical consumables market is projected to reach 185.2 billion yuan in 2024, with a year-on-year growth of 19.49% [4][30]. - The global medical device industry is also on an upward trend, with the market size expected to grow from 479.36 billion USD in 2023 to 637.96 billion USD by 2028 [4][18]. Competitive Position - Haisheng Medical's performance in terms of revenue growth is superior compared to its peers, with the company leading in revenue CAGR among comparable companies from 2022 to 2024 [12][14]. - The company has established a strong competitive edge through its proprietary technologies and extensive patent portfolio, which includes critical innovations in blood pressure sensors and bioelectrical signal acquisition [5][12].

此前，手术机器人的收费模式缺乏全国统一标准，大多依照手术入路、应用部位、国内外品牌等因素确 定。这种按设备收费的逻辑，不仅导致收费名目杂乱，甚至出现"开机费"等不合理项目，既增加患者负 担，也让医保难以实现精准有效介入。 "手术机器人代表了精准医疗的发展方向，其在手术中的参与程度和对精准手术的促进作用，决定了它 的临床价值。"国家医保局医药价格和招标采购司司长王小宁表示，此次发布的指南为手术机器人设立 了导航、参与执行、精准执行3个价格项目，让机器人收费实现"按劳取酬"。例如，通过超声技术为手 术提供可视化条件的机器人，可收取手术超声引导辅助操作费；通过手术机械臂平台，以映射控制方式 辅助医务人员操控手术器械，参与完成构建通道、打孔等手术步骤，可收取参与执行的手术机械臂辅助 操作费；只有辅助精准完成手术全部步骤或关键步骤时，才可收取与精准执行匹配的费用。 近日，国家医保局发布《手术和治疗辅助操作类医疗服务价格项目立项指南(试行)》。针对3D打印、手 术机械臂、远程手术等前沿医疗技术，该指南首次建立全国统一的收费框架，涵盖37项价格项目、5项 加收项及1项扩展项。这一举措以价格杠杆撬动医疗服务从"传统治疗"向" ...